These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16457651)

  • 41. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral vectors for dendritic cell-based immunotherapy.
    Jenne L; Schuler G; Steinkasserer A
    Trends Immunol; 2001 Feb; 22(2):102-7. PubMed ID: 11286712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells].
    Yang JY; Liu WC; Cao DY; Si XM; Teng ZH
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):728-32. PubMed ID: 18396682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.
    Qiu SJ; Lu L; Qiao C; Wang L; Wang Z; Xiao X; Qian S; Fung JJ; Ye SL; Bonham CA
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):429-38. PubMed ID: 15818505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes.
    Strobel I; Berchtold S; Götze A; Schulze U; Schuler G; Steinkasserer A
    Gene Ther; 2000 Dec; 7(23):2028-35. PubMed ID: 11175315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.
    Takayama T; Morelli AE; Robbins PD; Tahara H; Thomson AW
    Gene Ther; 2000 Aug; 7(15):1265-73. PubMed ID: 10918497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electroporation of dendritic cells with autologous total RNA from tumor material.
    Milano F; Krishnadath KK
    Methods Mol Biol; 2014; 1139():87-95. PubMed ID: 24619673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.
    Ahmed R; Sayegh N; Graciotti M; Kandalaft LE
    Curr Opin Biotechnol; 2020 Oct; 65():142-155. PubMed ID: 32240923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dendritic cell-based cancer immunotherapy.
    Engleman EG
    Semin Oncol; 2003 Jun; 30(3 Suppl 8):23-9. PubMed ID: 12881809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer.
    Wu Q; Xia D; Carlsen S; Xiang J
    Curr Gene Ther; 2005 Apr; 5(2):237-47. PubMed ID: 15853731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
    Tyagi RK; Mangal S; Garg N; Sharma PK
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Schadendorf D; Paschen A; Sun Y
    Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of large DNA viruses with dendritic cells.
    Jenne L; Thumann P; Steinkasserer A
    Immunobiology; 2001 Dec; 204(5):639-48. PubMed ID: 11846229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The first 1000 dendritic cell vaccinees.
    Ridgway D
    Cancer Invest; 2003; 21(6):873-86. PubMed ID: 14735692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lentiviral vectors in cancer immunotherapy.
    Oldham RA; Berinstein EM; Medin JA
    Immunotherapy; 2015; 7(3):271-84. PubMed ID: 25804479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.